Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
REVOLUTION MEDICINES INC (1RVMD.MI) Stock Price & Overview
BIT:1RVMD • US76155X1000
Current stock price
126.15 EUR
+43.15 (+51.99%)
Last:
The current stock price of 1RVMD.MI is 126.15 EUR. Today 1RVMD.MI is up by 51.99%.
1RVMD.MI Key Statistics
- Market Cap
- 24.999B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.05
- Dividend Yield
- N/A
1RVMD.MI Stock Performance
Today
+51.99%
1 Week
N/A
1 Month
N/A
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
1RVMD.MI Stock Chart
1RVMD.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1RVMD.MI.
Chartmill TA Rating
Chartmill Setup Rating
1RVMD.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1RVMD.MI. While 1RVMD.MI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
1RVMD.MI Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$1.86
Revenue Reported
EPS Surprise -15.36%
Revenue Surprise -100.00%
1RVMD.MI Forecast & Estimates
27 analysts have analysed 1RVMD.MI and the average price target is 115.11 EUR. This implies a price decrease of -8.76% is expected in the next year compared to the current price of 126.15.
For the next year, analysts expect an EPS growth of -33.36% and a revenue growth 1118.77% for 1RVMD.MI
Analysts
Analysts87.41
Price Target115.11 (-8.75%)
EPS Next Y-33.36%
Revenue Next Year1118.77%
1RVMD.MI Financial Highlights
Over the last trailing twelve months 1RVMD.MI reported a non-GAAP Earnings per Share(EPS) of -5.05. The EPS decreased by -65.55% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-1.13B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.05% | ||
| ROE | -69.35% | ||
| Debt/Equity | 0.16 |
Chartmill High Growth Momentum
EPS Q2Q%-66.07%
Sales Q2Q%N/A
EPS 1Y (TTM)-65.55%
Revenue 1Y (TTM)N/A
1RVMD.MI Ownership
Ownership
Inst Owners100.23%
Shares198.17M
Float190.64M
Ins Owners1.92%
Short Float %N/A
Short RatioN/A
1RVMD.MI Industry Overview
1RVMD.MI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
1RVMD.MI Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.82 | 40.797B | ||
| 1AE | ARGENX SE | 28.8 | 40.784B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.748B | ||
| ABVX | ABIVAX SA | N/A | 7.414B | ||
| 2X1 | ABIVAX SA | N/A | 7.402B | ||
| GXE | GALAPAGOS NV | N/A | 1.583B | ||
| GLPG | GALAPAGOS NV | N/A | 1.58B | ||
| NANO | NANOBIOTIX | N/A | 1.367B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1B | ||
| PHARM | PHARMING GROUP NV | 47.31 | 997.578M | ||
| PHGN | PHARMING GROUP NV | 47.15 | 992.281M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 954.74M | ||
| IVA | INVENTIVA SA | N/A | 873.421M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1RVMD.MI
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
IPO: 2020-02-13
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA US
Employees: 883
Phone: 13026365400
REVOLUTION MEDICINES INC / 1RVMD.MI FAQ
What does REVOLUTION MEDICINES INC do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
What is the current price of 1RVMD stock?
The current stock price of 1RVMD.MI is 126.15 EUR. The price increased by 51.99% in the last trading session.
Does 1RVMD stock pay dividends?
1RVMD.MI does not pay a dividend.
How is the ChartMill rating for REVOLUTION MEDICINES INC?
1RVMD.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for 1RVMD stock?
REVOLUTION MEDICINES INC (1RVMD.MI) currently has 883 employees.
What is REVOLUTION MEDICINES INC worth?
REVOLUTION MEDICINES INC (1RVMD.MI) has a market capitalization of 25.00B EUR. This makes 1RVMD.MI a Large Cap stock.